{"id":11214,"date":"2019-03-27T14:45:58","date_gmt":"2019-03-27T13:45:58","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=11214"},"modified":"2021-03-11T14:28:54","modified_gmt":"2021-03-11T13:28:54","slug":"camurus-har-genomfort-en-foretradesemission-om-cirka-403-miljoner-kronor","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/uppdrag\/camurus-har-genomfort-en-foretradesemission-om-cirka-403-miljoner-kronor\/","title":{"rendered":"Camurus har genomf\u00f6rt en f\u00f6retr\u00e4desemission om cirka 403 miljoner kronor"},"content":{"rendered":"<p class=\"preamble\">Camurus har genomf\u00f6rt en nyemission av aktier om cirka 403 miljoner kronor med f\u00f6retr\u00e4desr\u00e4tt f\u00f6r bolagets aktie\u00e4gare.<\/p>\n<p>Camurus \u00e4r ett svenskt forskningsbaserat l\u00e4kemedelsf\u00f6retag med fokus p\u00e5 utveckling och marknadsf\u00f6ring av differentierade och innovativa l\u00e4kemedel f\u00f6r behandling av sv\u00e5ra och kroniska sjukdomar. Produkterna baseras p\u00e5 den unika formuleringsteknologin FluidCrystal\u00ae samt en omfattande expertis inom alla faser av l\u00e4kemedelsutveckling. Den kliniska forskningsportf\u00f6ljen inneh\u00e5ller produkter f\u00f6r behandling av cancer, endokrina sjukdomar, sm\u00e4rta och beroende. Utvecklingen sker i egen regi och i partnerskap med internationella l\u00e4kemedelsbolag. Bolagets aktier \u00e4r noterade p\u00e5 Nasdaq Stockholm.<\/p>\n<p>Camurus har r\u00e5dgivits av Mannheimer Swartling i f\u00f6retr\u00e4desemissionen.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Camurus har genomf\u00f6rt en nyemission av aktier om cirka 403 miljoner kronor med f\u00f6retr\u00e4desr\u00e4tt f\u00f6r bolagets aktie\u00e4gare. Camurus \u00e4r ett svenskt forskningsbaserat l\u00e4kemedelsf\u00f6retag med fokus\u2026<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3469],"tags":[],"class_list":["post-11214","post","type-post","status-publish","format-standard","hentry","category-uppdrag","business-group-publik-ma-och-aktiemarknad"],"acf":[],"lang":"sv","translations":{"sv":11214,"en":11216},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/11214"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=11214"}],"version-history":[{"count":2,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/11214\/revisions"}],"predecessor-version":[{"id":14496,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/11214\/revisions\/14496"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=11214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=11214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=11214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}